Total Payments
$100,577
2024 Payments
$8,785
Companies
10
Transactions
77
Payment Breakdown by Category
Consulting$60,895 (60.5%)
Research$12,274 (12.2%)
Education$10,067 (10.0%)
Other$8,957 (8.9%)
Travel$6,824 (6.8%)
Food & Beverage$1,559 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $60,895 | 16 | 60.5% |
| Unspecified | $12,274 | 2 | 12.2% |
| Education | $10,067 | 13 | 10.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,957 | 5 | 8.9% |
| Travel and Lodging | $6,824 | 16 | 6.8% |
| Food and Beverage | $1,559 | 25 | 1.6% |
Payments by Type
General
$88,303
75 transactions
Research
$12,274
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35,018 | 17 | $0 (2024) |
| EMD Serono, Inc. | $33,461 | 34 | $0 (2023) |
| Genentech USA, Inc. | $9,717 | 4 | $0 (2021) |
| Merck KGaA | $6,715 | 2 | $0 (2024) |
| GENZYME CORPORATION | $4,999 | 8 | $0 (2018) |
| Celgene Corporation | $4,750 | 4 | $0 (2019) |
| Shire North American Group Inc | $3,324 | 4 | $0 (2018) |
| TG THERAPEUTICS, INC. | $2,400 | 1 | $0 (2021) |
| Genentech, Inc. | $169.95 | 2 | $0 (2024) |
| Biogen, Inc. | $22.55 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,785 | 3 | Novartis Pharmaceuticals Corporation ($5,190) |
| 2023 | $6,057 | 8 | EMD Serono, Inc. ($5,456) |
| 2022 | $18,548 | 8 | Novartis Pharmaceuticals Corporation ($12,697) |
| 2021 | $11,899 | 6 | Genentech USA, Inc. ($4,999) |
| 2020 | $5,778 | 2 | Novartis Pharmaceuticals Corporation ($5,190) |
| 2019 | $24,494 | 11 | EMD Serono, Inc. ($9,879) |
| 2018 | $17,802 | 27 | Novartis Pharmaceuticals Corporation ($6,131) |
| 2017 | $7,214 | 12 | EMD Serono, Inc. ($7,112) |
All Payment Transactions
77 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Merck KGaA | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,465.00 | General |
| 03/15/2024 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Consulting Fee | Cash or cash equivalent | $5,190.00 | General |
| Category: Neurology | ||||||
| 03/02/2024 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $130.00 | General |
| 10/25/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Travel and Lodging | In-kind items and services | $601.31 | General |
| 08/03/2023 | EMD Serono, Inc. | Evobrutinib | Consulting Fee | Cash or cash equivalent | $4,999.00 | General |
| 06/09/2023 | EMD Serono, Inc. | — | Travel and Lodging | Cash or cash equivalent | $276.64 | General |
| 06/09/2023 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $61.88 | General |
| 06/09/2023 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $56.25 | General |
| 06/09/2023 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $28.13 | General |
| 06/09/2023 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $16.88 | General |
| 06/09/2023 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $16.88 | General |
| 12/14/2022 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Consulting Fee | Cash or cash equivalent | $5,113.71 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2022 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $168.11 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2022 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Travel and Lodging | In-kind items and services | $139.71 | General |
| Category: NEUROSCIENCE | ||||||
| 08/29/2022 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $54.58 | General |
| 06/02/2022 | EMD Serono, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,096.86 | General |
| 05/25/2022 | EMD Serono, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $450.00 | General |
| 04/15/2022 | NOVARTIS PHARMACEUTICALS CORPORATION | ARZERRA (Drug) | — | In-kind items and services | $7,275.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH • Category: HEMATOLOGY | ||||||
| 02/24/2022 | Merck KGaA | — | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| 11/30/2021 | Genentech USA, Inc. | Enspryng (Biological) | Consulting Fee | Cash or cash equivalent | $2,104.00 | General |
| Category: Immunology | ||||||
| 11/06/2021 | TG THERAPEUTICS, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| 10/13/2021 | EMD Serono, Inc. | — | Education | In-kind items and services | $2,477.50 | General |
| 07/21/2021 | EMD Serono, Inc. | — | Education | In-kind items and services | $490.91 | General |
| 05/11/2021 | Genentech USA, Inc. | OCREVUS (Biological) | Consulting Fee | Cash or cash equivalent | $2,895.00 | General |
| Category: Immunology | ||||||
| 02/25/2021 | EMD Serono, Inc. | — | Education | In-kind items and services | $1,531.25 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $7,275 | 1 |
| Related to multiple studies | EMD Serono, Inc. | $4,999 | 1 |
About Dr. Olaf Stuve, MD
Dr. Olaf Stuve, MD is a Neurology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1760442420.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Olaf Stuve, MD has received a total of $100,577 in payments from pharmaceutical and medical device companies, with $8,785 received in 2024. These payments were reported across 77 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($60,895).
Ad
Practice Information
- Specialty Neurology
- Location Dallas, TX
- Active Since 03/27/2006
- Last Updated 07/08/2007
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1760442420
Products in Payments
- MAYZENT (Drug) $10,446
- ARZERRA (Drug) $7,275
- KESIMPTA (Drug) $5,422
- LEMTRADA (Drug) $4,999
- Evobrutinib $4,999
- Mavenclad (Biological) $4,997
- Non-Covered Product (Drug) $4,758
- Ozanimod (Drug) $4,750
- OCREVUS (Biological) $2,895
- Enspryng (Biological) $2,104
- GILENYA (Drug) $102.73
- Rebif (Biological) $69.66
- TYSABRI (Biological) $22.55
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Dallas
Nirav Pavasia, M.d, M.D
Neurology — Payments: $1.3M
Neurology $1.3M
Benjamin Greenberg, Md, MD
Neurology — Payments: $691,893
Neurology $691,893
Steven Herzog, M.d, M.D
Neurology — Payments: $519,302
Neurology $519,302
Waleed El-Feky, M.d, M.D
Neurology — Payments: $469,716
Neurology $469,716
Mark Alberts, Md, MD
Neurology — Payments: $417,917
Neurology $417,917
Adnan Subei, D.o, D.O
Neurology — Payments: $274,043
Neurology $274,043